Theme 9 Clinical trials and trial design

Acknowledgments

RK, YG, and CL are employees of Brainstorm Cell Therapeutics which provided support for this study. KR’s company is a vendor for the sponsor. NG, MC, JDB, KN, RHB, AJW, NS, RGM, and RB are site investigators for an ongoing trial sponsored by Brainstorm Cell Therapeutics.

Acknowledgments

The ALS Association. The Muscular Dystrophy Association

Acknowledgments

We wish to thank the patients who participated in FORTITUDE-ALS and their families for their contributions to the trial. Funding for this study was provided by Cytokinetics Inc.

Acknowledgments

We wish to thank the patients who participated in VITALITY-ALS and their families for their contributions to the trial. Funding was provided by Cytokinetics Inc.

Acknowledgments

We thank our participants for their contribution, and the Motor Neurone Disease Association (UK), NIHR CLRN and Walton Neuroscience Fund for research support.

Acknowledgments

Carolinas ALS Research Fund Carolinas Healthcare Foundation, Muscular Dystrophy Association Patient Services Grant

Acknowledgments

This study was sponsored by GSK and done in collaboration with McLaren Applied Technologies.

Acknowledgments

This study was sponsored by GSK and done in collaboration with McLaren Applied Technologies.

Acknowledgments

This study was sponsored by GSK and done in collaboration with McLaren Applied Technologies.

Acknowledgments

JS time supported by CReATe fellowship

Acknowledgments

This work was partially supported by grant UL1 TR001414 from the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through the Biostatistics, Epidemiology and Research Design Unit.

Acknowledgments

p-value communications provided editorial support. The study was funded and conducted by Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan (MTPC). All authors are employees of MTPC. JP is also an employee of Mitsubishi Tanabe Pharma Development America, Jersey City, NJ, USA.

Acknowledgments

p-value communications provided editorial support. The study was funded and conducted by MTPA. The authors are employees of MTPA, MTDA, or MTPC.

Acknowledgments

We thank all patients for taking part in their clinical trial.

Acknowledgments

The author thanks all patients and staff for this study.

Acknowledgments

CNPq (401922/2014-6)

Acknowledgments

The study was supported by JPND: SOPHIA (5/SOPHIA/JPND/2012) and NeedsinALS (DZP/2/JPND-II/2014).

Acknowledgments

We would like to thank patients and their families for taking part in this study. The study has been funded by a partnership including the ALS Association, GlaxoSmithKline, Harvard Stem Cell Institute and Massachusetts General Hospital Neurological Clinical Research Institute. B.J.W. is a co-inventor on a patent that may be relevant if future studies suggest ezogabine treatment could benefit patients with ALS.

Acknowledgments

Funding was provided by Cytokinetics Inc.

Acknowledgments

We wish to thank the participants who participated in FORTITUDE-ALS and their families for their contributions to the trial. Funding for this study was provided by Cytokinetics Inc.

Acknowledgments

The REFALS study is sponsored by Orion Pharma, Orion Corporation Finland

Acknowledgments

Study was supported by a grant from FightMND. KN and CR have an interest in Collaborative Medicinal Development.